HealthCap

SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial www.healthcap.eu/ovyg

Proud to be a member of the Board of Directors of BONESUPPORT AB! Important research trial which will change clinical practice (for my non-medical friends, this is NOT common). Kudos Emil Billbaeck Hakan Johansson and team for advancing the BoneSupport mission of "restoring health to improve the quality of life for patients with bone disorders"!

HealthCap divests 60% of its position in world leading orthopedics company Bonesupport! "Bonesupport’s impressive journey and its contributions to the field of orthopedics cannot be overstated. This is truly a fantastic company, one that HealthCap helped seed finance already in 2006. HealthCap remain Bonesupports fifth largest shareholder after the transaction and look forward to breaking new ground and bringing innovative solutions to the large patient population in need of bone void fillers." - Björn Odlander, Managing Partner HealthCap

We are happy to share exciting news from Aro today! Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD) www.healthcap.eu/fMuu

We are excited to announce our latest investment in Kivu Bioscience, developing next-gen ADC therapies.

Exciting and Important News from our Portfolio Company Ariceum Therapeutics that Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024 www.healthcap.eu/vfDi

SOLARIO study meets its primary endpoints - Bone substitute with local antibiotics enables reduced systemic antibiotic treatment BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces that the top-line results from the SOLARIO study show that patients with orthopedic infections, who were surgically treated with antibiotic-eluting bone substitute materials such as CERAMENT® G and CERAMENT® V, achieved equally good infection prevention with a short systemic antibiotic course of no more than seven days, compared to the previous standard treatment that extends over at least four weeks. The group that received the shorter antibiotic treatment exhibited significantly reduced side effects compared to standard treatment. "The new results from the SOLARIO study underscore the importance of integrating antibiotic-eluting bone substitute materials, such as CERAMENT G and CERAMENT V, into treatment guidelines for orthopedic infections. This approach not only promotes patient well-being by reducing the risk of side effects, but it also helps reduce the overall use of systemic antibiotics, which is crucial in the fight against antibiotic resistance (AMR)", states Professor Martin McNally, Nuffield Orthopaedic Centre, Oxford University Hospital. The full results from the SOLARIO study, conducted with funding from the European Bone & Joint Infection Society (EBJIS) and the National Institute for Health and Care Research (NIHR UK), are expected after publication. The SOLARIO* study is a randomized controlled multicenter trial involving 500 adult patients with orthopaedic infections. These patients were surgically treated with antibiotic-eluting bone substitute materials and received additional intravenous and/or oral systemic antibiotics for either at least four weeks (standard treatment) or a maximum of seven days (intervention treatment). The aim of the study is to demonstrate that antibiotic-eluting bone substitute materials enable a shortened duration of systemic antibiotic therapy, which could offer significant benefits for both patients and society. These benefits include shorter treatment times, reduced antibiotic costs, fewer side effects, better patient adherence, improved antibiotic stewardship, and a reduced risk of antibiotic resistance. *Dudareva M, Kumin M, Vach W, Kaier K, Ferguson J, McNally M, Scarborough M. Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO): a randomized controlled open-label non-inferiority trial of duration of systemic antibiotics in adults with orthopaedic infection treated operatively with local antibiotic therapy. Trials 2019; 20: 693. bit.ly/47H2VFc #BONESUPPORT #EBJIS #Orthopaedics #CERAMEN #AntibioticStewardship

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development www.healthcap.eu/pDLa

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 www.healthcap.eu/UzGG

🌟Thrilling news🌟     Additional data from SOLARIO study reveals further positive insights    "We are thrilled with the outcome of the SOLARIO study, which demonstrates how our innovative solutions can dramatically reduce the need for systemic antibiotics while maintaining excellent patient outcomes. This is a critical advancement in combating antimicrobial resistance while significantly reducing side effects," said Emil Billbäck, CEO of BONESUPPORT™.    Professor Martin McNally, Nuffield Orthopaedic Centre, Oxford University Hospital, who originally designed the SOLARIO trial said “For years we have added longer systemic antimicrobial therapy to our treatment regimes with little evidence of any benefit. This study shows clearly how we can improve our use of antimicrobials, without loss of efficacy. We can help patients to have a better experience, with fewer side effects. Surgeons can safely deliver high doses of antibiotics directly to the infection site at surgery, avoiding problems with compliance or antimicrobial resistance. A shift from long systemic courses to short systemic and local therapy is potentially a major contribution to global antibiotic stewardship.”    With an average reduction of 47 antibiotic days* per patient, CERAMENT® G and CERAMENT® V, continue to offer effective solutions in the surgical management of bone infections, while significantly lowering the adverse effects associated with prolonged antibiotic therapy. The results are poised to dramatically reshape clinical practices in managing bone infections and underscore the critical role local antibiotic eluting bone substitutes play in reducing systemic antibiotic use, a major victory for antimicrobial stewardship, patient safety, and well-being. *Total antibiotic days – each antibiotic on each day reported separately – many of the antibiotics are prescribed in combination dosages.    For more details on the key highlights from the SOLARIO study:   bit.ly/3ByxNvL    #BONESUPPORT #EBJIS #Orthopaedics #CERAMENT #AntibioticStewardship #SOLARIO